Lyell Immunopharma, Inc. (LYEL)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch LYEL
See up to 3 months of LYEL. The 7-day demo opens the 1M and 3M ranges and puts LYEL on your watchlist.
Start 7-day demoLatest LYEL insider trades
About Lyell Immunopharma, Inc. (LYEL)
The SEC lists Lyell Immunopharma, Inc. under CIK 0001806952, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
LYEL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 11 | 14,208 | $215K |
| Grant or award | 1 | 47,500 | |
| Other acquisition / disposition | 2 | 82,500 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
LYEL insider transactions (Form 4)
3060 Form 4 filings on record, the earliest from Nov 1, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jarrad Mattieu Aguirre - Officer | Open-market sale | Common Stock | 422 footnote F1 | $8.63 footnote F2 | $4K | |
| ||||||
| David Shook - Officer | Open-market sale | Common Stock | 500 footnote F1 | $12.70 footnote F2 | $6K | |
| ||||||
| Jarrad Mattieu Aguirre - Officer | Grant or award | Option (right to buy) | 47,500 | $0.00 | - | |
 Lynn Seely - Officer | Open-market sale | Common Stock | 9,589 footnote F1 | $15.54 | $149K | |
| ||||||
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 989 footnote F1 | $15.54 | $15K | |
| ||||||
| Gary K. Lee - Officer | Open-market sale | Common Stock | 1,457 footnote F1 | $15.54 | $23K | |
| ||||||
| Veronica Sanchez Bulis - Officer | Open-market sale | Common Stock | 621 footnote F1 | $14.34 footnote F2 | $9K | |
| ||||||
| Gary K. Lee - Officer | Open-market sale | Common Stock | 131 footnote F1 | $14.34 footnote F2 | $2K | |
| ||||||
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 89 footnote F1 | $14.34 footnote F2 | $1K | |
| ||||||
| Lynn Seely - Officer | Open-market sale | Common Stock | 390 footnote F1 | $14.34 footnote F2 | $6K | |
| ||||||
| Innovative Cellular Therapeutics Holdings Ltd - 10% Owner | Other | Common Stock | 44,000 footnote F1 | $0.00 | - | |
| ||||||
| Innovative Cellular Therapeutics Holdings Ltd - 10% Owner | Other | Common Stock | 38,500 footnote F1 | $0.00 | - | |
| ||||||
| Innovative Cellular Therapeutics Holdings Ltd | Open-market sale | Common Stock | 10 | $13.70 | $137 | |
| Innovative Cellular Therapeutics Holdings Ltd | Open-market sale | Common Stock | 10 | $13.73 | $137 | |
| Innovative Cellular Therapeutics Holdings Ltd | Other | Common Stock | 76,000 footnote F1 | $0.00 | - | |
| ||||||
| Innovative Cellular Therapeutics Holdings Ltd | Other | Common Stock | 66,500 footnote F1 | $0.00 | - | |
| ||||||
| Lynn Seely - Officer | Open-market sale | Common Stock | 388 footnote F1 | $18.91 footnote F2 | $7K | |
| ||||||
| Gary K. Lee - Officer | Open-market sale | Common Stock | 130 footnote F1 | $18.92 footnote F2 | $2K | |
| ||||||
| Stephen J. Hill - Officer | Open-market sale | Common Stock | 89 footnote F1 | $18.92 footnote F2 | $2K | |
| ||||||
| Veronica Sanchez Bulis - Officer | Open-market sale | Common Stock | 217 footnote F1 | $18.91 footnote F2 | $4K | |
| ||||||
| William Jl Rieflin | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Sumant Ramachandra | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Elizabeth G. Nabel | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Richard Klausner | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Cathy Friedman | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Otis W. Brawley | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| Mark Bachleda | Grant or award | Option (right to buy) | 9,250 | $0.00 | - | |
| David Shook - Officer | Open-market sale | Common Stock | 1,977 footnote F1 | $12.64 | $25K | |
| ||||||
| Smital Shah - Officer | Grant or award | Option (right to buy) | 140,000 | $0.00 | - | |
| ARCH Venture Partners IX, LLC - 10% Owner | Open-market purchase | Common Stock | 488,090 | $25.61 | $12.50M | |
Item 8.01, 9.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
LYEL insider trading FAQ
What is the latest insider trade for LYEL?
Lyell Immunopharma, Inc. (LYEL) had 14 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for LYEL runs to 60 Form 4 filings, the earliest from 2024-11-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying LYEL stock?
No insider purchases of LYEL were filed in the last 90 days. 3 purchases are on record for this company.
How many insiders are selling LYEL stock?
11 insider sales of LYEL were filed in the last 90 days, totaling $215K.
Where can I see LYEL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects LYEL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jarrad Mattieu Aguirre view on EDGAR
- - David Shook view on EDGAR
- - Jarrad Mattieu Aguirre view on EDGAR
- - Lynn Seely view on EDGAR
- - Stephen J. Hill view on EDGAR
- - Gary K. Lee view on EDGAR
- - Veronica Sanchez Bulis view on EDGAR
- - Gary K. Lee view on EDGAR
- - Stephen J. Hill view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Insider activity in Health Care
- Where LYEL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow LYEL with a 7-day demo
- LYEL on your watchlist
- Every LYEL Form 4 filing on record
- Up to 3 months of LYEL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
